Dose-related effects of anthracyclines on right ventricular function
| Variable | None | Low-dose <300 mg/m2 | High-dose >300 mg/m2 | Adjusted p value* |
| Number | 57 (55.3) | 24 (23.3) | 22 (21.4) | |
| FAC (%) | 41.6±4.2 | 42.0±4.3 | 38.3±7.6 | 0.033d |
| TAPSE (mm) | 21.3±3.6 | 20.4±3.5 | 20.0±4.0 | 0.303a |
| RV-s’ (cm/s) | 11.7±2.1 | 10.8±2.4 (n=23) | 10.2±2.3 | 0.045a |
| RIMP | 0.45±0.09 (n=55) | 0.46±0.09 (n=23) | 0.44±0.11 | 0.955a |
| RVFWS (%) | −27.7±3.6 (n=50) | −27.7±4.6 (n=23) | −25.2±4.7 | 0.034b,d |
| TRP (mm Hg) | 17.8±3.6 (n=44) | 18.7±3.8 (n=15) | 18.3±5.3 (n=17) | 0.656a |
| 2D-LVEF (%) | 57.0±4.7 | 54.5±7.1 | 51.1±5.0 | <0.001 b,d |
| GLS (%) | −17.9±2.1 (n=55) | −17.0±2.2 (n=23) | −16.8±2.2 (n=21) | 0.024d |
| Elevated filling pressures | 10 (17.5) | 2 (8.3) | 10 (45.5) | 0.002b,d |
Data presented as mean±SD, or n (%). Calculations with χ2.
*Analysis of covariance (ANCOVA) adjusted for age at examination, heart rate, body mass index, diastolic blood pressure. Statistically significant values in boldface (p<0.05). Post hoc Bonferroni: aNo significant difference between treatment groups. bSignificant difference (<0.05) between ‘high dose >300 mg/m2’ and ‘low dose <300 mg/m2'. cSignificant difference (<0.05) between ‘high dose >300 mg/m2‘ and ‘low dose <300 mg/m2’ with ‘no anthracycline’. dSignificant difference (<0.05) between ‘high dose >300 mg/m2’ and ‘no anthracycline’.
2D, two dimensions; FAC, fractional area change; GLS, global longitudinal strain; LVEF, left ventricular ejection fraction; RA, right atrium; RIMP, Right ventricular index of myocardial performance; RV, right ventricular; RVFWS, RV-free-wall strain; RVIDd, RV-Internal Dimension in diastole; RV-s', RV-peak systolic velocity; TAPSE, tricuspid annular plane systolic excursion; TRP, tricuspid regurgitation pressure.